Search

Displaying results 2321 - 2330 of 9669 in total
  1. Drug

    Nadroparin

    go.drugbank.com/drugs/DB08813
    ApprovedInvestigationalWithdrawn

    It is derived from porcine sources and has a mean molecular size of 5000 daltons. … Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

  2. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

  3. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    [L47036,L47057,L4274,L4278] Globally, it is estimated that approximately 35 to 50 percent of Fabry patients may have amenable GLA variants that are treatable with migalastat. … [L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate.

  4. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    It has once again been approved and should soon be available on the French and Australian market. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.

  5. Drug

    Bacillus calmette-guerin substrain russian BCG-I live antigen

    go.drugbank.com/drugs/DB16648
    ApprovedInvestigational

    It was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734] … [L32734] It is to be marketed by Verity Pharmaceuticals, under the trade name VERITY-BCG, and manufactured by the Serum Institute of India.

  6. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872Products: GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT 100 TABLET, GRAZAX 75.000 SQ-T ORAL LIYOFILIZAT TABLET, 30 ADET
  7. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

  8. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.

  9. Drug

    Oxycodegol

    go.drugbank.com/drugs/DB14146
    Investigational

    Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263]. … Nektar Therapeutics has filed an application for FDA approval of Loxicodegol for use in the treatment of chronic lower back pain [L3263]

  10. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    It is widely used as a sugar substitute and in "sugar-free" food products. … It works by inhibiting the growth of the microorganisms present in plaque and saliva after it accummulates intracellularly into the microorganism [A32423].